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Albendazole (ABZ, anti-parasitic active pharmaceutical ingredient) is a crystalline low water-soluble
drug, thus the dissolution rate in gastrointestinal fluids is limited. Consequently, the improvement of
the water solubility and dissolution rate of ABZ implies a great challenge for a more efficient treatment
of hydatidosis. In this context, SBA-15 and SBA-16 ordered mesoporous silica materials were synthetized
and loaded with ABZ. X-ray diffraction, FT-IR spectroscopy, nitrogen physisorption manometry, particle
size distribution and scanning electronic microscopy were used to characterize unloaded and loaded
materials (ABZ/SBA-15 and ABZ/SBA-16). The loaded ABZ amount in the carriers was estimated by ele-
mental analysis. For the loaded materials, the drug solubility and release profile were evaluated. In addi-
tion, mathematical models were compared to explain the dissolution kinetics of ABZ from mesoporous
solids. ABZ was successfully loaded into the mesopores. The amorphous state of the adsorbed ABZ was
confirmed by differential scanning calorimetry that resulted in a notable increment in the dissolution rate
compared to crystalline ABZ. Drug release behaviors were well simulated by the Weibull model for ABZ/
SBA-15 and by the Gompertz function for pure ABZ and ABZ/SBA-16. The SBA-15 carrier exhibited the
highest drug loading and dissolution rate becoming a promising material to improve ABZ bioavailability.
 2019 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human echinococcosis is a parasitic infection produced by tape-
worms of the genus Echinococcus. This parasite attacks canines,
which house the adult worm in the intestine. When sheep or cattle
ingest contaminated canine feces, they become the intermediate
hosts and if canines consume lamb or beef containing the larvae
the cycle is completed. Persons can be infected due to the ingestionof food, soil and water contaminated with parasite eggs or by direct
contact with animal hosts. The disease can be presented mainly in
two forms: cystic echinococcosis (hydatidosis) and alveolar
echinococcosis caused by Echinococcus granulosus and E. multilocu-
laris, respectively. These two forms are of medical and public
health relevance, especially in endemic regions (Argentina, Peru,
East Africa, Central Asia and China) where human incidence rates
for cystic echinococcosis are 50 per 100.000 person-years, and
prevalence levels higher than 10%. In the year 2015, the World
Health Organization (WHO) estimated that echinococcosis pro-
duces 19.300 deaths and about 871.000 disability-adjusted life-
years globally each year. Annual costs associated with this disease
are estimated to be US$ 3 billion for treating cases and losses to the
livestock industry (WHO, 2019).
Hydatidosis is characterized by the presence of one or more
hydatid cysts (i.e., slow growing fluid-filled structures that contain
the larvae) located mainly in the liver and lungs. There are four
main ways to treat this disease: medication, percutaneous treat-
ment, surgery, and the watch and wait method for non-active cystsas car-
2 M. Esperanza Adrover et al. / Saudi Pharmaceutical Journal xxx (xxxx) xxx(Brunetti and Junghanss, 2009). Antiparasitic drugs (benzoimida-
zole carbamates) constitute the better option in non-complex cysts
or cysts located in non-vital parts of the body, and in persons in
which surgery is hazardous. Also, medicine treatment decreases
the danger of recurrence when is used previously or after surgery
and percutaneous treatments (Anadol et al., 2001). Several investi-
gators and clinicians consider Albendazole (ABZ) the drug of choice
to treat hydatidosis. The drug dosage is of 15 mg/kg/day (400 mg
tablets, two daily intakes) for 3–6 months (Falagas and Bliziotis,
2007; Stamatakos et al., 2009). Recently, Fattahi Masoom et al.
(2017) reported a study of the efficacy of ABZ administered for a
long period of time (six months divided in three 8-week stages,
each stage comprising of six weeks treatment followed by two
weeks without medication). The cure rate in persons who finished
one, two, and three stages were 7.5%, 21.7% and 66.1%, respec-
tively. Thus, the administration scheme evaluated, which com-
prises stages of no treatment, seems to produce better results in
comparison to the continuous treatment. As it can be seen, the
treatment with ABZ implies a high dose and long period of treat-
ment. These inconveniences may be mainly associated to the low
water solubility of the drug (0.2 lg/mL at 25 C) that limits the dis-
solution rate in the gastrointestinal fluids. Consequently, the drug
absorption rate is poor and erratic, producing low drug levels in
plasma (Pensel et al., 2015, 2014). Therefore, the increment of
the aqueous solubility and dissolution rate of ABZ implies a great
challenge to achieve a more efficient treatment of hydatidosis. In
this sense, different technologies were used to increase the solubil-
ity/dissolution rate of ABZ, such as: (i) solid dispersions (Castro
et al., 2010; Jiménez de los Santos et al., 2017; Kohri et al., 1999;
Martinez-Marcos et al., 2016), (ii) complexation with
b-cyclodextrins (Chattah et al., 2017; Evrard et al., 2002; García
et al., 2014; Palomares-Alonso et al., 2010) and acyclic cucurbit
[n]uril molecular containers (Ma et al., 2012), (iii) co-griding with
various excipients by jet-mill (Vogt et al., 2008), (iv)
extrusion/spheronization (Ibrahim and Al-Anazi, 2013), (v) emulsi-
fication/solvent evaporation methods (Abulaihaiti et al., 2015;
Souza and Marchetti, 2012), (vi) spray-drying (García et al.,
2013b, 2013a; Ibrahim et al., 2014; Priotti et al., 2017), vii) high
pressure homogenization combined with spray-drying (Paredes
et al., 2016), (viii) solvent recrystallization and spherical agglomer-
ation (Thakur et al., 2015), (ix) encapsulation in liposomes (Haitao
et al., 2016; Li et al., 2015; Panwar et al., 2010) and (x) nanoformu-
lations (Movahedi et al., 2017). In general, these techniques require
numerous production stages, several materials and organics sol-
vents. A more direct technique than the previously mentioned is
to load low water-soluble drug into different types of carriers,
e.g., micelles (Panja et al., 2016), mesoporous silica nanoparticles
(Abbaraju, 2017; Jambhrunkar et al., 2013; Lu et al., 2007), and
polymer-modified inorganic nanoparticles (Panja et al., 2015;
Panja et al., 2016). To the best of our knowledge, the strategy to
direct load ABZ into ordered mesoporous silica materials in order
to enhance the solubility/dissolution rate of the drug has not been
previously investigated. Ordered mesoporous silica particles are
nontoxic and biocompatible materials and have several attractive
characteristics to improve drug dissolution, such as: high surface
area, large pore volume, and long-range ordered pore structure.
In addition, these carriers show higher resistance to heat, pH and
stability on storage in comparison to many polymers commonly
used to enhance drug solubility. The porous structure of ordered
mesoporous silica materials permit the confinement and stabiliza-
tion of drug molecules within the pores in an amorphous state that
improves the drug solubility/dissolution rate in comparison to the
crystalline state (Li et al., 2012; Mccarthy et al., 2015). In this sense,
the ordered mesoporous silica particles SBA-15 and SBA-16 are
promising materials for improving drug delivery due to their
dual-porosity system. This means that SBA materials presentPlease cite this article as: M. Esperanza Adrover, M. Pedernera, M. Bonne et al.,
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mal and hydrothermal stability. SBA-15 has hexagonal pores in a
2D array while SBA-16 presents a 3D body-centered cubic arrange-
ment (Stevens et al., 2006) (Hu et al., 2012). As summarized in the
review reported by Xu et al. (2013) (Xu et al., 2013), SBA-15 was
proposed as a carrier of different low water-soluble drugs, (e.g.,
ezetimibe, fenofibrate, glibenclamide, ibuprofen, indomethacin,
itraconazole, telmisartan and griseofulvin). Additionally, in-vivo
studies of poor-water soluble drugs such as carbamazepine, fenofi-
brate and ketoprofen with SBA-15 as carrier were reported
(Riikonen et al., 2018). On the other hand, there is a lower number
of studies focusing on SBA-16 as carrier for hydrophobic drugs
(Zhang and Cresswell, 2016). Thomas et al. (2010) (Thomas et al.,
2010) produced SBA-16 for loading antiepileptic drugs (oxcar-
bazepine, rufinamide and carbamazepine). The incorporation of
these drugs within the mesoporous solids leads to an effective par-
ticle size decrease improving dissolution rates. Hu et al. (2011) (Hu
et al., 2011) studied the SBA-16 material for the delivery of the
non-steroidal anti-inflammatory agent indomethacin (water-
insoluble drug). The drug exhibited a marked enhancement in
the dissolution rate after being loaded into the silica particles. In
addition, Hu et al. (2012) (Hu et al., 2012) compared the dissolu-
tion profiles for carvedilol loaded into 3D cubic SBA-16 and 2D
hexagonal MCM-41 (mesoporous material), displaying for SBA-16
a more fast release in comparison with MCM-41.
In this context, the novelty of this work was to load ABZ into
ordered mesoporous silica materials in order to augment the solu-
bility/dissolution rate of the drug. For this purpose, the materials
SBA-15 and SBA-16 were synthetized and loaded with ABZ by
the immersion method in order to compare their behavior as a
platform for bioapplication. X-ray diffraction and scanning elec-
tronic microscopy were employed to characterize SBA-15 and
SBA-16. FT-IR, nitrogen sorptometry and thermogravimetry–differ
ential scanning calorimetry were carried out to compare the syn-
thesized unloaded (SBA-15 and SBA-16) and the loaded materials
(ABZ/SBA-15 and ABZ/SBA-16). The amount of ABZ loaded in the
carriers was estimated by elemental analysis. For the loaded mate-
rials the drug solubility and release profile were evaluated. In addi-
tion, mathematical models were compared to describe the
dissolution kinetics of ABZ from mesoporous silica materials.2. Experimental section
2.1. Materials
Tetraethyl orthosilicate (TEOS), Pluronic P123, Pluronic F127
were obtained from Sigma Aldrich (Germany). The solvents buta-
nol, acetic acid, hydrochloric acid were purchased from Anedra
(Argentina) and crystalline albendazole from Parafarm (98.52%
purity) (Argentina). The spectroscopic grade potassium bromide
was obtained from Merck (Germany). All reagents were of analyt-
ical grade and were employed as received from the supplier.2.2. Synthesis of ordered mesoporous silica carriers: SBA-15 and SBA-
16
The synthesis of the SBA-15 silica material was realized accord-
ing to the protocol proposed by Zhao et al. (1998) (Zhao et al.,
1998) and modified by Belmoujahid et al. (2015) (Belmoujahid
et al., 2015). First, Pluronic P123 was dissolved in hydrochloric
solution at 40 C. After total dissolution TEOS was added, the med-
ium was kept at 40 C and stirred for 2 h. The composition of the
obtained gel was: 1 TEOS: 0.017 P123: 5.68 HCl: 197 H2O. The
hydrothermal synthesis was carried out for 24 h in an oven at
90 C in a sealed polypropylene bottle. The solid material wasSynthesis and characterization of mesoporous SBA-15 and SBA-16 as car-
ttps://doi.org/10.1016/j.jsps.2019.11.002
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dried overnight in an oven at 70 C. The solid was then calcined
in a muffle furnace at 300 C under air for 4 h with a heating rate
of 1 C/min.
SBA-16 was synthesized following the procedure reported by
Gobin et al. (2007) (Gobin et al., 2007) with a gel composition of:
1 TEOS: 0.003 F127: 0.8 HCl: 1.8 C4H9OH: 120 H2O. Pluronic
F127 was dissolved in hydrochloric solution. After 30 min of agita-
tion, butanol was added as co-surfactant. Next, TEOS was added
and stirred during 24 h at ambient temperature (25 C). The mix-
ture was poured into a Teflon autoclave and heated for 48 h in
an oven at 60 C. Finally, the material was washed with tri-
distillated water by means of three 30 min centrifugation cycles
(at 5000 rpm). Subsequently, the synthesized material was dried
in an oven at 70 C for one night. The obtained solid was calcined
for 6 h in a muffle furnace at 500 C for 6 h with a heating rate of
2 C/min.2.3. Drug loading procedure
The immersion method was used to load ABZ onto the SBA-15
and SBA-16. To this end, 1250 mg of ABZ was dissolved in 25 mL
of acetic acid up to completely dissolution. Then, 419 mg of
ordered mesoporous silica particles were added. The sample was
kept under stirring for 48 h at ambient temperature (25 C). Subse-
quently, the sample was centrifuged for 30 min at 8000 rpm to
separate the supernatant from the precipitated solid (ABZ/SBA-15
and ABZ/SBA-16). Firstly, the materials were dried at room temper-
ature for 72 h. Then, the solids were heated at 60 C using a mois-
ture analyzer with halogen heating (model M45, Ohaus, Pine
Brook, USA) until constant weight was reached.2.4. Powder X-ray diffraction
The pore structure of the materials was determined by X-ray
diffraction in a Bruker D2 Phaser device using CuK radiation (k =
1.54 Å) with a Ni filter, with step 0.01, with divergent slots and
convergent 0.1 mm and 3 mm respectively, 10 mA current, the
30 kV voltage using a LYNXEYE detector.2.5. Scanning electron microscopy and particle size distribution
The morphology of SBA-15 and SBA-16 was assayed by a scan-
ning electron microscopy (SEM, JEOL 35CF) with an acceleration
potential of 10 kV. The samples were dried under air flow on a
porthole and posteriorly were metalized with gold coating (thick-
ness of 245 Å) (PELCO 91,000 sputter coater). A transmission elec-
tron microscopy (TEM, JEOL, 100 CX) with an acceleration potential
of 100 kV was employed. The samples were prepared by dispersing
the powder in an ethanol solution and placed in an ultrasonic bath
for 15 min. Then, few drops were placed on a holey carbon film on
200 mesh grids.
Both SEM and TEM digitized images were processed by means
of Fiji software in order to measure the particle maximum Feret
diameter (i.e., the longest dimension of the particle).2.6. Fourier transform infrared (FTIR) spectroscopy
The chemical identity of pure materials (SBA-15, SBA-16, ABZ)
and the loaded ones (ABZ/SBA-15 and ABZ/SBA-16) was verified
by diffuse reflectance infrared Fourier transform spectroscopy
(DRIFTS, Nicolet 6700FT-IR spectrometer). The samples were
mixed with KBr and the IR spectra (average scans = 64,
resolution = 4 cm1) were obtained between 400 and 4000 cm1.Please cite this article as: M. Esperanza Adrover, M. Pedernera, M. Bonne et al.,
riers to improve albendazole dissolution rate, Saudi Pharmaceutical Journal, h2.7. Nitrogen physisorption manometry analysis
The specific surface area of the materials was analyzed by N2
adsorption–desorption isotherms at 77 K by means of the
Brunauer-Emmet-Teller method (BET) multipoint method P/P0 val-
ues between 0.05 and 0.35. The analysis was carried out in the
Autosorb iQ gas sorption analyzer (Quantachrome Instruments).
Prior to analysis, SBA-15 and SBA-16 were degassed and dried at
200 C for 7 h, while ABZ/SBA-15 and ABZ/SBA-16 were degassed
and dried at 60 C for 24 h. The pore size distributions (PSDs) were
obtained using the Barrett-Joyner-Halenda (BJH) model. (Sapag,
2011).
The microporous volume and the microporous surface area
were determined using the Harkins and Jura t-plot (Galarneau
et al., 2014).
2.8. Elemental analysis
The loading efficiency of ABZ in SBA-15 and SBA-16 was evalu-
ated by elemental analysis (C, H, and N) employing an Exeter Ana-
lytical CE-440 apparatus (Exeter Analytical). The weights of the
samples ranged between 1.59 and 1.64 mg.
2.9. Differential scanning calorimetry
The physical state of the pure drug and the loaded mesoporous
silica samples were examined by differential scanning calorimetry
(DSC) (Pyris 1, Perkin Elmer). The thermographs of each sample
were performed under continuous flow of N2 (10 mL/min) and a
temperature ramp of 10 C/min from a temperature of 25 C up
to 260 C.
2.10. Solubility studies
Three stoppered flasks with 2 mg/mL of ABZ (concentration 25
times higher than the reported drug solubility in 5 mL HCl 0.1 N
solutions at 37 C) were used for pure ABZ (Elsamaligy, 2014). Like-
wise, an equivalent amount of drug content for ABZ/SBA-15 and
ABZ/SBA-16 were employed to evaluate ABZ solubility from the
loaded materials. These powders were suspended in 5 mL HCl
0.1 N solution at 37 C. The samples were stored 4 days in order
to reach the solubility equilibrium and were periodically shaken.
Posteriorly, samples were filtered through a 0.45 lm membrane
filter and were quantified spectrophotometrically at 290 nm (max-
imum absorption wavelength of ABZ in HCl 0.1 N) (T60U
spectrophotometer).
2.11. Dissolution rate of ABZ from SBA-15 and SBA-16
The rate of dissolution of ABZ from SBA-15 and SBA-16 in com-
parison to pure ABZ was assessed using a dissolution apparatus II
under sink conditions (708-DS, Dissolution Apparatus, Agilent
Technologies). A volume of 900 mL of HCl 0.1 N (pH 1.2) was used
as dissolution medium at 37 C with a paddle rotation speed of
100 rpm (Zhong et al., 2016). About 10.0 mg of pure ABZ,
33.0 mg of ABZ/SBA-15 and 78.2 mg of ABZ/SBA-16 were incorpo-
rated to each dissolution vessel. The amount of ABZ-loaded carriers
was defined in order to contain about 10 mg of ABZ for comparison
purposes. At defined time intervals, samples of 5 mL were taken
and in order to maintain a constant volume fresh medium was
added (at 37 C) (Agilent 8000, Dissolution Sampling Station, Agi-
lent Technologies). The ABZ concentration was measured with a
UV–visible spectrophotometer at 290 nm (T60U spectrophotome-
ter). The assays were done in triplicate and mean values are
informed.Synthesis and characterization of mesoporous SBA-15 and SBA-16 as car-
ttps://doi.org/10.1016/j.jsps.2019.11.002
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The ABZ and ABZ-loaded carriers release kinetics were analyzed
by employing the Probit model (Tsong et al., 1997a, 1997b) (Eq.
(1)), the Gompertz model (Costa et al., 2003) (Eq. (2)), the Weibull
function (Langenbucher, 1972) (Eq. (3)) and the logistic function
(Costa and Lobo, 2001; Tsong et al., 1997b) (Eq. (4)).
F ¼ FmaxU aþ blogtð Þ ð1Þ
F ¼ FmaxeaeðblogtÞ ð2Þ
F ¼ Fmax 1 e t
b
a
  
ð3Þ
F ¼ Fmax e
/þblogtð Þ
1þ e /þblogtð Þ
 
ð4Þ
where F is the fraction (%) of drug released in time t and Fmax is
the maximum fraction of the drug released at infinite time. a is the
scale parameter in each model and is related to the time scale of
the process. Whereas b is the acceleration or shape parameter
associated with the dissolution rate per unit of time. In Eq. (1), U
is the standard normal distribution of dissolution profile.
In Equations (2–4), the kinetic parameters were obtained after
linearization while the parameters in Eq. (1) were adjusted mini-
mizing the sum of squared errors between the experimental and
drug released fractions calculated from the cumulative distribution
function. Additionally, the accuracy of the obtained parameters
was validated by means of the DDSolver software (Zhang et al.,
2010).
The Akaike Information Criteria (AIC) was used in this study to
evaluate the goodness of the release models employed to describe
the dissolution profiles (Simionato et al., 2018). The AIC is defined
by equation (5):
AIC ¼ nln WSSRð Þ þ 2p ð5Þ
where n is the number of dissolution measurements, p is the
number of parameters that were adjusted in each model, WSSR is
the weight sum of square residues. When comparing mathematical
models, a smaller AIC value leads to a better fit.
3. Results and discussion
3.1. Characterization of SBA-15 and SBA-16 parent materials
3.1.1. X-ray diffraction
Fig. 1a shows the X-ray diffraction pattern of SBA-15. The XRD
data showed a well resolved pattern with a prominent peak at 2h
ca. 0.9 and two peaks at 2h ca. 1.62 and 1.8 for the synthesized0 1 2 3 4
110
In
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2θ
100
210
a)
Fig. 1. XRD diffraction patterns o
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(110) = 5.45 nm and (210) = 4.9 nm that are in accordance with val-
ues previously reported for this material (Newalkar and Katsuki,
2000). These planes are characteristic for the P6mm symmetry
group (Fulvio et al., 2005). The unit cell dimension estimated as
a0 = d100 (2/31/2) has a value of 11.3 nm. X-ray diffraction pattern
of SBA-16 at Fig. 1b reveals its three-dimensional cubic cage struc-
ture (Im3m space group). This pattern shows a very strong peak at
2h ca. 0.78 and a small peak corresponding to 2h ca. 1.1 in agree-
ment with the data reported in literature (Wang et al., 2004). The
corresponding d-spacings are (110) = 11.3 nm and (220) = 8.03 nm.
Both reflections yield a unit cell parameter of a0 = 16 nm confirm-
ing that the measured structure is indeed the Im3m SBA-16 struc-
ture. It should be noted that if the structure was hexagonal or
lamellar, the shoulder would be at a completely different position.
Other informed patterns of SBA-16 materials present similar unit
cell parameters (Andrade et al., 2012; Grudzien et al., 2007).3.1.2. Particles’ morphology, size, and pore structure
The SEM images showed a rod-like shape for SBA-15 particles
with a uniform rod length around 0.5–1.5 lm (Fig. 2a). The
described morphology was in accordance with the one reported
by Belmoujahid et al. (2015) (Belmoujahid et al., 2015). On the
other hand, most SBA-16 particles exhibited an irregular shape
(Fig. 2b) similar to the morphology found by Feliczak-guzik et al.
(2016) (Feliczak-guzik et al., 2016). The maximum Feret diameter
of SBA-16 particles was between 5 and 10 mm. TEM was employed
to corroborate the ordered pore structure of SBA-15 and SBA-16.
The microphotographs revealed that the materials were greatly
porous. SBA-15 showed a mean pore size around 5 nm (measured
through image analysis) and a periodical well-organized hexagonal
array was detected once the electron beam was perpendicular to
the main axis of the material (i.e., vertical orientation) (Fig. 2c).
For parallel orientation (i.e., electron beam parallel to the main
axis), a channel structure of the mesopores with parallel stripes
was observed (Fig. 2d). These results verified the typical two-
dimensional structure of the material (Wang et al., 2012). For
SBA-16 the mean pore size was about 6 nm (measured from the
images). Unidirectional pore channels were observed at vertical
orientation (Fig. 2e). For the parallel orientation the usual cubic
arranged and uniform pore arrays were shown (Fig. 2f) (de
Oliveira Freitas et al., 2015). Therefore, TEM images verified the
ordered structure of the synthesized materials.3.1.3. FT-IR and N2 sorption analyses of SBA-15, SBA-16 materials
before and after ABZ loading
Fig. 3a exhibits FT-IR spectroscopy of pure ABZ. The absorption
peak related to the stretching vibration mode of amide N-H was
found at around 3323 cm1. The absorption band from the alipha-0 1 2 3 4
In
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 2θ
110
200
b)
f: (a) SBA-15 and (b) SBA-16.
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Fig. 2. SEM images: (a) SBA-15 (2000x) and (b) SBA-16 (480x). TEM images (270000x): at vertical orientation (c) SBA-15, (e) SBA-16 and at parallel orientation d) SBA-15, f)
SBA-16.
M. Esperanza Adrover et al. / Saudi Pharmaceutical Journal xxx (xxxx) xxx 5tic hydrocarbon group (C-H) was observed at around 2960 cm1.
The peak located at about 1713 cm1 showed the ester C=O bond
of the carbamate portion of the drug. The peak at around
1623 cm1 presented the aromatic C=C bond, which together with
the amide N-H bond represent the benzimidazole portion of the
ABZ molecule. The band at around 1523 cm1 showed the stretch-
ing vibration mode of the C=N group. Thus, FTIR spectroscopy
revealed the usual bands of pure ABZ (Koradia et al., 2018;
Tavares Cavalcanti et al., 2012). In addition, the FT-IR spectra con-
firmed the chemical nature of SBA-15 and SBA-16 carriers (Fig. 3b).
An absorption band at around 3739 cm1 presented the symmetri-
cal stretching vibration mode of O-H bond related to silanol (Si-
OH) groups. A wide intense peak at 3500–3300 cm1 and a peak
at around 1630 cm1 were associated to the O-H bending and
stretching vibration mode of the water molecules adsorbed on
the material surface. The peaks situated at 1080 cm1 and
800 cm1 were assigned to the anti-symmetric vibrations of non-
bonding oxygen atoms (Si-O) of Si-OH and symmetric stretchingPlease cite this article as: M. Esperanza Adrover, M. Pedernera, M. Bonne et al.,
riers to improve albendazole dissolution rate, Saudi Pharmaceutical Journal, hvibrations of Si-O-Si group, respectively. The peak corresponding
to the internal vibration between Si-O-Si tetrahedral of SBA-15
and SBA-16 was observed at around 460 cm1. Also, the typical
band related to the stretching vibration of Si-OH group appeared
at 970 cm1 (Chen et al., 2011; Ghosh et al., 2015; Giraldo et al.,
2014; Zhang et al., 2016). After the drug loading, the FT-IR spectra
still presented the typical band of SBA-15 and SBA-16 (at
1080 cm1) demonstrating that the surface chemistry of the mate-
rials was not modified (Fig. 3c). Moreover, the presence of ABZ in
the mesoporous carriers was recognized by the FT-IR spectroscopy.
For ABZ/SBA-15 several different bands related to ABZ were found
at: 3323 cm1(N-H), 2960 cm1(C-H), 1713 cm1(C=O=),
1623 cm1 (C=C) and 1523 cm1 (C=N). The ABZ/SBA-16 sample
also revealed the presence of ABZ in the mesoporous silica. The
peak related to ABZ at 3323 cm1 was not detected but the peak
at 1713 cm1 appeared with a similar intensity to the one pre-
sented in the spectrum of ABZ/SBA-15. The bands at around
1623 cm1 and 1523 cm1 presented lower intensity than the cor-Synthesis and characterization of mesoporous SBA-15 and SBA-16 as car-
ttps://doi.org/10.1016/j.jsps.2019.11.002
Fig. 3. FT-IR spectra of (a) ABZ, (b) SBA-15 and SBA-16, and (c) SBA-15/ABZ and SBA-16/ABZ.
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suggest that a lower percentage of ABZ was loaded in SBA-16 in
comparison to SBA-15. Posteriorly, these results were confirmed
by sorption isotherms and elemental analysis.
Fig. 4 presents the N2 adsorption/desorption isotherms and pore
size distributions (PSDs) for SBA-15 and ABZ/SBA-15 (Fig. 4a), and
SBA-16 and ABZ/SBA-16 (Fig. 4b). Parent SBA-15 and SBA-16 mate-
rials exhibited type IV isotherms characteristic of mesoporous
solids with microporous content. SBA-15 isotherm presented H1
hysteresis loop typical of mesoporous materials with one dimen-
sional cylindrical channels opened at both sides (Gonzalez et al.,
2018) (Fig. 4a). Instead, SBA-16 showed H2 hysteresis loop at the
high relative pressure region characteristic of uniform cage-like
mesoporous materials with interconnected pores (Fig. 4a) (Xu
et al., 2007). It is important to highlight that PSDs of SBA-15 and
ABZ/SBA-15 were derived from the desorption branch of nitrogen
isotherm by using the BJH model. On the other hand, for SBA-160.0 0.2 0.4 0.6 0.8 1.0
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Fig. 4. Nitrogen sorption isotherms and pore size distribution (inset)
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branch. This branch was selected because the cage-like pore struc-
ture presents percolation phenomenon on the desorption branch
(Sapag, 2011). From the PSDs it was observed that the average pore
sizes of SBA-15 and SBA-16 were 5.6 nm for both materials which
is in good agreement with the TEM results.
The nitrogen sorption isotherms of both SBA-15 and SBA-16
showed a reduction in the total volume of adsorbed nitrogen after
ABZ loading; indicating a significant pore filling of the mesoporous
carriers (Fig. 4). In addition, SBA-15/ABZ showed a more significant
reduction in the pore size than SBA-16/ABZ. Even though the sur-
face area changed, the shape of the isotherms remained the same
after drug loading, indicating that the mesoporous texture of carri-
ers was preserved.
Table 1 presents the following textural properties of SBA-15 and
SBA-16 before and after drug loading: BET surface area, total pore
volume, microporous surface area and micropore volume calcu-0.0 0.2 0.4 0.6 0.8 1.0
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of: (a) SBA-15 and ABZ/SBA-15 and (b) SBA-16 and ABZ/SBA-16.
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method. BET surface area of SBA-15 and SBA-16 presented similar
values. However, the total pore volume of SBA-16 is significantly
lower than the total pore volume of SBA-15. After drug loading,
decreases in BET surface area, total pore volume, micropore surface
area and micropore volume were observed. These changes can be
explained by the loading of ABZ into pores of mesoporous silica.
These results are in good agreement with FT-IR and N2 sorption
data indicating that the drug was loaded in the materials. Conse-
quently, in order to quantify the amount of loaded drug in the
mesoporous carriers, elemental analysis was done showing a drug
loading of 30.3 wt% and 12.8 wt% for SBA-15 and SBA-16 samples,
respectively.25 50 75 100 125 150 175 200 225 250
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Fig. 5. DSC patterns of ABZ, SBA-15, SBA-16, ABZ/SBA-15 and ABZ/SBA-16.
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Fig. 6. Release profiles of pure ABZ, ABZ/SBA-15 and ABZ/SBA-16.3.2. Solubility and dissolution studies
The solubility study showed that pure crystalline ABZ had a
very low solubility value of 0.0152 ± 0.0002 mg/mL in acid medium
(HCl 0.1 N). Instead, ABZ loaded in the mesoporous materials pre-
sented an increment in the drug solubility in comparison to the
pure ABZ: 0.0171 ± 0.0011 mg/mL and 0.0190 ± 0.0013 mg/mL
for ABZ/SBA-16 and ABZ/SBA-15, respectively. These results could
be related to the porous structure of the mesoporous materials,
which produce a restrictive effect that did not allow the formation
of the drug crystalline form. Indeed, the drug molecules were lim-
ited and stabilized inside the pores in an amorphous state
(Mccarthy et al., 2015). Crystalline solids have a high crystal pack-
ing energy that is disrupted during the solubilization process. On
the other hand, amorphous solids possess low packing energy
and no long-range order of molecular packing. These characteris-
tics produce that drugs in amorphous state commonly exhibits
greater solubility than the crystalline solids (Kim et al., 2008;
Zhong et al., 2016). The change of the ABZ structure from crys-
talline to amorphous state was corroborated through DSC analysis.
As it can be seen in Fig. 5, the thermograms of ABZ/SBA-15 and
ABZ/ SBA-16 samples did not show the typical melting endother-
mic peak of crystalline ABZ (at 209 C (Tavares Cavalcanti et al.,
2012)) demonstrating the amorphous state of the drug. ABZ/SBA-
15 showed higher solubility than ABZ/SBA-16. Regarding these
results, the two mesoporous materials presented similar surface
area and pore size; hence the higher solubility of ABZ/SBA-15
may be attributed to the large total pore volume of this material
in comparison to ABZ/SBA-16 (Table 1). The great volume of pores
first produced a better soaking of the drug and consequently gen-
erated better contact with the medium, which leads to an increase
in the solubility of the drug (Zhong et al., 2016). In Fig. 6, the dis-
solution profiles showed a notable increment of the release rate of
the loaded drug. In particular, ABZ/SBA-15 and ABZ/SBA-16
released around 50% of the drug at 5 min of the assay in compar-
ison to pure ABZ that only released about 1% at this point time.
Notably, SBA-15 released around 98 ± 2% of the drug in 2 h, becom-
ing a promising candidate platform to improve ABZ oral bioavail-
ability. The higher dissolution rate of ABZ/SBA-15 in comparisonTable 1
Textural properties of SBA-15 and SBA-16 materials.
Sample SBETa
(m2/g)
Vtb
(cm
SBA-15 387 0.63
SBA-16 409 0.36
ABZ/SBA-15 152 0.28
ABZ/SBA-16 222 0.21
a BET specific surface area.
b Total pore volume.
c Micropore surface area calculated using the t-plot method.
d Micropore volume calculated using the t-plot method.
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previously mentioned together with the 2D hexagonal array of
the mesopores. In this sense, Porras Quevedo et al. (2017) (Porras
Quevedo et al., 2017) reported a greater release rate of ibuprofen3/g)
Smc
(m2/g)
Vmd
(cm3/g)
8 31 0.013
1 105 0.048
6 0 0.000
4 27 0.011
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Table 2
ABZ, ABZ/SBA-15 and ABZ/SBA-16 kinetics parameters according to Probit, Gompertz, Weibull and logistic models.
Model Statistics ABZ ABZ/SBA-15 ABZ/SBA-16
Probit a 4.32 0.76 1.04
b 2.83 1.04 2.14
r2 1.00 1.00 1.00
AIC 11.96 1.98 8.76
Gompertz a 25.53 1.76 3.81
b 2.10 1.04 3.21
r2 1.00 1.00 1.00
AIC 11.44 4.14 6.57
Weibull a 639.12 3.03 3.26
b 1.82 0.52 0.82
r2 1.00 1.00 1.00
AIC 16.45 1.19 11.93
Logistic a 7.43 1.23 1.85
b 4.92 1.59 3.67
r2 1.00 1.00 1.00
AIC 13.04 1.85 6.93
Bold numbers correspond to the best fit.
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mesoporous materials.
As ABZ/SBA-15 is a promising candidate platform to improve
ABZ oral bioavailability, a stability test of SBA-15 was carried
out. This test was performed under the same conditions chosen
for the drug loading procedure (i.e., concentrated acetic acid,
48 h at ambient temperature). The BET area of SBA-15 before and
after the acidic treatment was 387 and 389 m2/g, respectively.
Therefore, these results verified that SBA-15 was unaffected by
acetic acid exposure. Similar results were found by El Mourabit
et al. (2012) when SBA-15 was attacked by phosphoric acid.
3.3. Release modeling
The dissolution profiles corresponding to ABZ, ABZ/SBA-15 and
ABZ/SBA-16 were evaluated by fitting experimental data to the
Probit, Gompertz, Weibull and logistic models. The parameters
for each kinetics equation, the determination coefficient (r2) as
well as Akaike Information Criteria (AIC) values are listed in Table 2.
These latter values were used to evaluate the goodness of the
release models. Based on determination coefficient (r2) as well as
AIC, the Gompertz model is the function that best fit the dissolu-
tion data of ABZ and ABZ/SBA-16 while the Weibull model fits
properly the dissolution data of ABZ/SBA-15. In this sense, the
Gompertz model is more useful for comparing the release profiles
of drugs having an intermediate release rate as ABZ and ABZ/SBA-
16. This model has a sharp increment in the beginning and con-
verges slowly to the asymptotic maximal dissolution
(Lokhandwala et al., 2013). On the other hand, the Weibull model
is more appropriate for comparing the release profiles of drug
loaded into carriers, which significantly increase the drug dissolu-
tion rate. In Table 2, it is possible to observe that the shape param-
eter b of Weibull equation is higher than 1 for ABZ describing a
sigmoid shape with upward curvature followed by a turning point.
For ABZ/SBA-15 and ABZ/SBA-16, the shape parameter bwas lower
than 1 because those dissolution profiles presented an initial slope
higher than the corresponding one of ABZ. After that, the dissolu-
tion profiles were consistent with an exponential function (Costa
and Lobo, 2001). The models that best represent the dissolution
experimental data were shown in Fig. 6 in order to demonstrate
the goodness of the parameters fit.
4. Conclusions
In the present work the synthesized SBA-15 and SBA-16 pre-
sented the typical structure, morphogy and textural properties ofPlease cite this article as: M. Esperanza Adrover, M. Pedernera, M. Bonne et al.,
riers to improve albendazole dissolution rate, Saudi Pharmaceutical Journal, hthese mesoporous materials. ABZ was effectively loaded into the
mesopores of the carriers in an amorphous state resulting in a
increment in the solubility. In addition, a notable increment in
the dissolution rate in comparison to the pure crystalline drug
was achieved. The Weibull model properly described the ABZ-
SBA-15 release profile. On the other hand, the Gompertz function
accurately fitted the pure ABZ and ABZ/SBA-16 dissolution profiles.
The SBA-15 carrier showed the highest drug loading and dissolu-
tion rate becoming a promising plataform to enhance ABZ oral
bioavailability. The ABZ/SBA-15 is a powder whose production is
simple and potentially scalable. Besides, the material could be for-
mulated in common oral pharmaceutical dosage forms as capsules.
Further investigations are required to evaluate the in-vivo pharma-
cokinetic performance of ABZ/SBA-15 as a suitable alternative for
the human echinococcosis treatment.
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